Clinical Trial

GRI Bio Announces Closing of $8.0 Million Public Offering

LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a…

2 months ago

NervGen Pharma Announces Proposed Amendment to Warrants

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"),…

2 months ago

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a…

2 months ago

CluePoints Scoops Prestigious 2025 Scrip Award

RBQM and AI leader wins the 'Best Contract Research Organization – Specialist Providers' categoryKING OF PRUSSIA, Pa., Dec. 12, 2025…

2 months ago

Cadrenal’s Quiet Expansion Play Is Starting to Get Loud

PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) entered the back half of the…

2 months ago

Cadrenal’s Anticoagulation Platform Is Expanding in a $40 Billion Market

PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) believes it continues to be misread…

2 months ago

Parexel Named “Best Contract Research Organization” at 21st Annual Scrip Awards

Industry leader recognized for excellence and innovation in clinical developmentRALEIGH, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading…

2 months ago

Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability…

2 months ago

Additional Confirmed Response Reported as Part of Amplia Investor Presentation

HIGHLIGHTS An additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate…

2 months ago

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics,…

2 months ago